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  ABSTRACT 
  Objectives      The mechanism of action of treatment with 
tumour necrosis factor (TNF) blockers in rheumatoid 
arthritis (RA) is still not completely understood. The aim 
of this study was to test if adalimumab treatment could 
affect the inﬂ  ux of monocytes into the synovium.   
  Methods      A novel technique was used to analyse the 
migration of labelled autologous monocytes before 
and 14 days after initiation of adalimumab treatment 
using scintigraphy. CD14 monocytes were isolated from 
patients with RA, using a positive selection procedure 
with magnetic-activated cell sorting, and labelled with 
technetium-99m-hexamethylpropylene-amino-oxime. 
Scintigraphic scans were made 1, 2 and 3 h after 
re-infusion.  
  Results      As early as 14 days after the start of treatment 
with adalimumab a signiﬁ  cant decrease in disease activity 
score evaluated in 28 joints was shown. There was no 
signiﬁ  cant decrease in the inﬂ  ux of monocytes into the 
joint at this time.   
  Conclusions      This study indicates that adalimumab 
treatment does not reduce the inﬂ  ux of monocytes 
into the synovium early after initiation of treatment. As 
previous studies showed a rapid decrease in macrophage 
inﬁ  ltration after TNF-antibody therapy, which could not 
be explained by increased cell death, this points to an 
important role for enhanced efﬂ  ux of inﬂ  ammatory cells 
from  the  synovium.      
  INTRODUCTION 
  Disease control has been improved by the use of 
tumour necrosis factor (TNF) blockade in patients 
with rheumatoid arthritis (RA) and other immune-
mediated inﬂ   ammatory diseases. However, the 
mechanisms by which TNF antagonists exert their 
effect is still not completely understood.    1    Anti-TNF 
antibody treatment has been shown to result in 
marked reduction of synovial inﬂ  ammation in RA 
and psoriatic arthritis.    2       –       4    This decrease in synovial 
cellularity could be observed as early as 24–48 h 
after initiation of treatment.    5       –       7    
  This early reduction in synovial inﬂ  ammation 
after TNF blockade could not be explained by 
apoptosis induction at the site of inﬂ  ammation,    6        7    
leaving either reduced cell inﬂ  ux or enhanced cell 
efﬂ  ux to explain this process. In one study inﬂ  ix-
imab treatment signiﬁ  cantly decreased the inﬂ  ux 
of   111  In-labelled granulocyte migration into affected 
joints of RA patients,    4    and in another study adali-
mumab signiﬁ  cantly reduced inﬂ  ux of   99  Tc-labelled 
leucocytes, whereas no decrease in inﬂ  ux was seen 
in patients treated with placebo.    8    
  Monocytes and macrophages are key players in 
the pathogenesis of RA.    9    Furthermore, the decrease 
in macrophage numbers in the synovium is asso-
ciated with clinical improvement after effective 
treatment.    10    Therefore, the effect of adalimumab 
treatment on monocyte migration towards the 
synovial compartment was examined. The authors 
recently developed a procedure using a combi-
nation of immunomagnetic cell selection with 
CD14-coated beads, labelling with technetium-
  99m-hexamethylpropylene-amino-oxime and scin-
tigraphy to visualise the migratory behaviour of 
autologous monocytes.    11    Applying this method, 
a continuous migration of monocytes into the 
inﬂ  amed synovial tissue of RA patients at a slow 
macrophage-replacement rate was shown.    12    The 
slow rate of monocyte inﬂ   ux into the synovial 
compartment suggests that the rapid effect of 
anti-TNF therapy on macrophage inﬁ  ltration can-
not merely be explained by blockade of cell inﬂ  ux, 
as previously thought. Hence, this novel imaging 
technique was used to directly test if adalimumab 
treatment could affect the inﬂ  ux of monocytes into 
the synovium.   
  PATIENTS  AND  METHODS 
  Patients 
  Eight patients with established RA according to the 
revised American College of Rheumatology criteria 
for the diagnosis of RA    13    were included. All patients 
had an indication for the use of anti-TNF therapy 
according to the guidelines of the Dutch Society for 
Rheumatology, which is active disease status (dis-
ease activity score evaluated in 28 joints (DAS28) 
≥3.2) despite treatment with two conventional 
disease-modifying antirheumatic drugs. In this 
study all patients started with adalimumab (40 mg 
subcutaneously every other week) 24 h after the 
baseline scans. Three patients used maximally tol-
erable methotrexate at a stable dosage (10–25 mg/
week). The others received adalimumab mono-
therapy. The use of concomitant non-steroidal anti-
inﬂ  ammatory drugs was permitted if stable for at 
least 1 month prior to baseline and was kept stable 
throughout the study. All patients provided written 
informed consent and approval was granted by the 
local medical ethics committee.   
    Isolation and labelling of monocytes 
  Isolation and labelling of monocytes was performed 
as described previously (see supplementary text).   
    Scintigraphy and signal calculations 
  Scintigraphy and signal calculations were done 
as described previously (see supplementary text). 
This procedure was done at day −14, baseline and 
day 14.   
  ▶  Additional data 
  (supplementary data, tables and 
ﬁ  gures) are published online 
only at (http://ard.bmj.com)
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  DISCUSSION 
  The results of this mechanistic study indicate that CD14 mono-
cyte inﬂ  ux into the synovium is not decreased 2 weeks after 
the start of adalimumab treatment. Earlier, TNF blockade was 
shown not to induce apoptosis in the synovium early after ini-
tiation of treatment, although the possibility cannot be excluded 
that more long-term treatment would lead to a more pro-apop-
totic state, being a result of dampening of inﬂ  ammation rather 
than its cause.    1    This suggests that the rapid decrease in synovial 
macrophage numbers observed after anti-TNF treatment can-
not be explained by an immediate effect on monocyte inﬂ  ux, 
as previously hypothesised. These data strengthen the recent 
observation that monocytes migrate towards the inﬂ  amed RA 
synovium at a slow macrophage-replacement rate,    12    which 
already suggested that blockade of monocyte migration would 
be insufﬁ  cient to explain the rapid reduction of macrophage 
  Statistical  analysis 
  Data were analysed using the Wilcoxon signed ranks test to 
determine signiﬁ  cant changes from baseline. Correlations were 
calculated using the Spearman’s rank correlation coefﬁ  cient. 
Values are expressed as median and IQR. The calculations were 
performed with SPSS 16.0 for Windows.     
  RESULTS 
  Patient  characteristics 
  Half of the patients were IgM rheumatoid factor positive and 
all had erosive disease. Their median age was 53 (48.5–57) 
years and median disease duration was 162 (119–273) months. 
Individual patient characteristics are shown in   table 1  .   
  Monocyte  inﬂ  ux is stable and not markedly decreased early 
after initiation of adalimumab treatment 
  Scans were made 14 days prior to the start of adalimumab treat-
ment, at baseline and 14 days after the start of adalimumab 
treatment (see supplementary   ﬁ  gure 1  ). The number of labelled 
monocytes in the joint of interest per patient was comparable 
1, 2 and 3 h after re-infusion. This was true for day −14, base-
line and day 14 (see supplementary table). Monocyte inﬂ  ux per 
patient at 3 h postinfusion is shown in   ﬁ  gure 1  . Of interest, there 
was no signiﬁ  cant change in monocyte inﬂ  ux 1, 2 and 3 h after 
re-infusion from day −14 to day 1, which was before the start 
of adalimumab treatment (p=0.33, p=0.67, p=0.21 respectively). 
The heterogeneity between patients is consistent with changes 
in synovial macrophages that were found in serial biopsies of 
patients treated with placebo.    14    Importantly, the inﬂ  ux of mono-
cytes did not decrease after re-infusion of monocytes comparing 
day 14 to baseline, indicating that adalimumab treatment did 
not affect the inﬂ  ux of monocytes early after initiation of treat-
ment (  ﬁ  gure 1  ).     
  Clinical  beneﬁ  t of adalimumab treatment 
  The change in DAS28 from screening to day 84 is shown in 
  ﬁ  gure 2  . The median DAS28 at baseline was 5.9 (4.8–7.2). The 
DAS28 did not change signiﬁ   cantly between screening and 
baseline (p=0.58). There was a statistically signiﬁ  cant decrease 
in median DAS28 from baseline to day 14 of 1.2 (0.72–1.8, 
p=0.01). At day 84 the median DAS28 had decreased to 2.8 (2.5–
3.6) (  ﬁ  gure 2  ). Three patients were European League Against 
Rheumatism (EULAR) moderate responders to treatment and 
ﬁ  ve were EULAR good responders. There was no correlation 
between the decrease in DAS28, erythrocyte sedimentation rate 
or C reactive protein and the change in monocyte inﬂ  ux into the 
joints at 1, 2 or 3 h after re-infusion from baseline to 14 days (see 
supplementary   ﬁ  gure 2  ).       
  Figure  1          Number of monocytes in joint of interest 3 h post re-infusion 
per patient at day −14, 1 and 14.       
  Figure  2       DAS28  from  screening  to  day  84.    
  Table  1       Baseline  patient  characteristics  
   Patient  1   Patient  2   Patient  3   Patient  4   Patient  5   Patient  6   Patient  7   Patient  8 
TJC of 28 joints 4 6 25 16 12 23 4 17
SJC of 28 joints 3 6 4 12 6 20 15 7
VAS general disease activity 47 19 87 71 59 89 70 67
ESR (mm/h) 35 6 97 14 10 43 58 16
C reactive protein (mg/l) 4.6 7.2 85.6 5.9 5.1 17.5 34.7 3.0
DAS28 4.75 3.58 7.58 5.91 5.06 7.82 6.03 5.3
Sex (0=male) 0 0 0 1 1 1 1 0
Age (years) 59 53 39 58 47 53 53 54
Disease duration (months) 114 264 132 42 456 168 276 156
Rheumatoid factor (1=positive) 1 0 0 1 0 1 1 0
Erosive disease (1=yes) 1 1 1 1 1 1 1 1
      DAS28, disease activity score in 28 joints; ESR, erythrocyte sedimentation rate; SJC, swollen joint count; TJC, tender joint count; VAS, visual analogue scale.     
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numbers found after anti-TNF treatment. Consistent with the 
hypothesis that TNF blockade does not interfere with high lev-
els of monocyte inﬂ  ux into the synovial compartment, numbers 
of peripheral blood monocytes were not increased after initia-
tion of inﬂ  iximab treatment.    7    This lack of reduction in monocyte 
inﬂ  ux is in contrast with previous work showing a reduction 
of labelled neutrophils into affected joints after treatment with 
TNFα blockers.    4        8    Of note, there is a clear difference in replace-
ment rate for neutrophils compared to monocytes, as large num-
bers of neutrophils trafﬁ  c into the synovial ﬂ  uid.    15    In addition, 
the difference might be explained in part by the differential use 
of adhesion molecules between neutrophils and monocytes. 
Very late antigen-4/vascular cell adhesion molecule-1 (VLA-4/
VCAM-1) dependent rolling is seen mostly in monocytes, 
whereas adhesion of neutrophils is very much dependent on 
lymphocyte function-associated antigen 1/inter cellular adhe-
sion molecule-1.    16    The reduced serum levels of sICAM-1 but 
not sVCAM-1 (reﬂ  ecting expression of adhesion molecules by 
endothelial cells) after administration of inﬂ  iximab could per-
haps explain the sustained inﬂ  ux of monocytes while neutrophil 
inﬂ  ux is reduced.    17    
  In contrast to sVCAM-1 levels in peripheral blood, VCAM-1 
expression in the synovial tissue is reduced after anti-TNF treat-
ment.    3        7    VCAM-1 is especially highly expressed by ﬁ  broblast-
like synoviocytes, and may play a crucial role in retention and 
survival of inﬁ  ltrating  monocytes/macrophages.    18    Similarly, 
ICAM-1 expression is decreased in the tissue after TNF block-
ade. Thus, decreased expression of adhesion molecules    3    as well 
as chemokines    4    in the tissue may facilitate macrophage egress 
from the synovium, resulting in decreased macrophage numbers 
in the synovial tissue. In line with increased cell egress after anti-
TNF treatment, it was found that anti-TNF therapy results in 
increased lymphatic vessel formation in the synovium.    19    
  Taken together, these data suggest that at this early time point 
the anti-inﬂ  ammatory effect of treatment with TNF blockers 
can only partly be explained by downregulation of vascular 
adhesion molecules on endothelial cells and subsequent reduc-
tion in migration of inﬂ  ammatory cells into the joint. Anti-TNF 
treatment may diminish RA disease activity by decreasing 
inﬂ  ammatory cell retention in the synovial tissue, for example, 
by reducing integrins expressed by ﬁ  broblast-like synoviocytes. 
Accordingly, treatments aimed at integrins such as anti-LFA-1 
(efatizumab) and anti-VLA-4 were shown to be effective treat-
ment in inﬂ  ammatory diseases, although serious infectious side 
effects were reported.    20        21    
  In conclusion, this study indicates that treatment with adali-
mumab does not reduce the inﬂ  ux of monocytes into the syn-
ovium 2 weeks after the start of treatment. In previous work 
early reduction in synovial inﬂ  ammation after TNF blockade 
could not be explained by apoptosis induction at the site of 
inﬂ  ammation. Based on these studies, it is hypothesised that 
efﬂ  ux of inﬂ  ammatory cells is a major contributor to the rapid 
reduction of cellularity after initiation of anti-TNF antibody 
therapy.       
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